BeOne Medicines (ONC) Cash from Operations (2015 - 2026)

BeOne Medicines (ONC) has reported Cash from Operations for 12 consecutive years, with $462.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Operations rose 75.58% year-over-year to $462.8 million in Q2 2026; TTM through Jun 2026 was $1.5 billion, a 159.81% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 901.8% from the prior year.
• Cash from Operations was $462.8 million for Q2 2026 at BeOne Medicines, up from $201.3 million in the prior quarter.
• Over five years, Cash from Operations peaked at $462.8 million in Q2 2026 and troughed at -$563.8 million in Q1 2023.
• A 5-year average of -$55.7 million and a median of -$86.9 million in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations plunged 289.11% in 2022 and surged 455.28% in 2025, its largest moves.
• Over 5 years, Cash from Operations stood at -$318.2 million in 2022, then jumped by 30.34% to -$221.6 million in 2023, then jumped by 133.91% to $75.2 million in 2024, then surged by 455.28% to $417.3 million in 2025, then increased by 10.9% to $462.8 million in 2026.
• The last three Cash from Operations figures came in at $462.8 million (Q2 2026), $201.3 million (Q1 2026), and $417.3 million (Q4 2025), per Business Quant data.